CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to determine the safety, pharmacokinetics,
pharmacodynamics and efficacy and activity of seviteronel, a lyase-selective inhibitor of
CYP17, in patients with advanced breast cancer.